Navigation Links
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
Date:8/8/2013

have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer.  Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com.

OncoGenex' Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our anticipated product development activities, such as expected clinical trial completion and design, statements regarding the potential benefits and potential development of our product candidates and statements regarding our future expenses and the use and adequacy of our cash resources. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that our product candidates will not demonstrate the hypothesized or expected benefits, the risk of delays in our expected clinical trials, the risk that new developments in the rapidly evolving cancer therapy landscape require changes in our clinical trial plans or limit the potential benefits of our product candidates and the other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including the Company's Annual Rep
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. OncoGenex Announces Multiple Trials in Progress Presentations at the 2013 ASCO Annual Meeting
2. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013
3. OncoGenex Pharmaceuticals, Inc. Provides Update on Clinical Development Program and Reports Financial Results for Fourth Quarter and Year End 2012
4. OncoGenex Announces Plans for the Initiation of the Borealis-2 Clinical Trial Evaluating OGX-427 in Combination with Second-Line Therapy for Bladder Cancer
5. OncoGenex Announces Initiation of the Phase 3 "AFFINITY" Trial for Patients with Advanced Prostate Cancer
6. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
7. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity Growth Conference
8. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
9. Imprimis Pharmaceuticals, Inc. to Present at the Southern California Investor Conference on Thursday, August 8, 2013 at the Island Hotel in Newport Beach, CA. The presentation is scheduled to begin at 11 a.m. ET / 8 a.m. PT
10. OPTIMER PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Investigates Possible Breaches of Fiduciary Duty by Board of Optimer Pharmaceuticals, Inc. in Connection with Sale of Company to Cubist Pharmaceuticals, Inc.
11. Auxilium Pharmaceuticals, Inc, Announces Second Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 23, 2014 In industries such ... sectors, the machines are more and more connected and ... amounts of data are being harvested by numerous sensors ... number of connected machines is estimated at several dozen ... raises the fundamental question as to how big data ...
(Date:9/23/2014)... DUBLIN , Sept. 23, 2014 ... the "Company"), a biotechnology company pioneering the manufacturing ... in emerging nations, today announced that the Depository ... for DTC,s Deposit and Withdrawal at Custodian ("DWAC") ... ("FAST") transfer agent as the distribution point.  The ...
(Date:9/23/2014)... 2014 This test can detect HIV infection if ... defined by activities that can transfer body fluids from one ... any shared needles. , An in-vitro diagnostic home-use ... HIV test works by looking for your body,s response to ... minutes, enabling patients to learn their status in a single ...
Breaking Medicine Technology:TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 2TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 3TNI BioTech, Inc. Announces Its Stock is Now DTC DWAC/FAST Eligible 4WholeHealth Products announces the release of the FDA Cleared "HIV 1&2" Rapid Diagnostic Test for Professional and Retail 2
... - Ambrilia,Biopharma Inc. (TSX:AMB), a biopharmaceutical company developing,novel ... and,cancer, held its Annual General and Special Meeting ... novel series of HIV,integrase inhibitors and recent developments ... Chairman of the Board, Mr. Frederic,Porte, and a ...
... 2007 /PRNewswire/ -- Results of the,Option (TOcilizumab ... first multinational Phase III study outside,of Japan, ... 4mg/kg,or 8mg/kg) plus methotrexate achieved a significant ... symptoms of moderate to,severe rheumatoid arthritis (RA) ...
Cached Medicine Technology:Ambrilia Highlights Encouraging Data for its HIV Integrase,Inhibitor Program and Recent Developments at Annual Meeting 2Ambrilia Highlights Encouraging Data for its HIV Integrase,Inhibitor Program and Recent Developments at Annual Meeting 3Ambrilia Highlights Encouraging Data for its HIV Integrase,Inhibitor Program and Recent Developments at Annual Meeting 4Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 2Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 3Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 4Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid,Arthritis Compared to a Current Standard of Care 5
(Date:9/23/2014)... 2014 Mirena IUD lawsuits ( http://www.themirenalawsuitcenter.com/ ... migration of the birth control device continue to mount ... According to court documents dated September 18th, an Iowa ... the IUD outside of the uterus caused the device ... is now pending in the U.S. District Court, Northern ...
(Date:9/23/2014)... 2014 The inaugural single day event ... Hotel New Otani Tokyo Gardens in Tokyo. Clinical data scientists ... and validation. , The second single day event in ... offices in Shanghai. The clinical data scientists attending this event ... figures and listings, which display data collected in clinical studies ...
(Date:9/23/2014)... Oakland, CA (PRWEB) September 23, 2014 ... Cannabis Industry Today . In its first post, the ... quickly growing and changing cannabis industry. , The cannabis ... , Colorado alone is expecting an 18-month boost of ... medicinal and adult use pot sales. And, the new ...
(Date:9/23/2014)... 23, 2014 Florida Hospital Zephyrhills ... renovated Women’s Health Center on Wednesday, September 24. ... the specially designed center offers a new level ... County. The Women’s Health Center offers comprehensive women’s ... labor and delivery through The Baby Place®, and ...
(Date:9/23/2014)... A new analysis of published studies found that ... cancer versus benign disease in regions where infections ... of lung lesions suspicious for cancer could lead ... additional potential complications and mortality. , Histoplasmosis ... that are often concentrated in bird droppings and ...
Breaking Medicine News(10 mins):Health News:Mirena IUD Lawsuit News: New Complaint Filed On Behalf of Iowa Woman Claims Mirena Migrated to Her Rectum, Bernstein Liebhard LLP Reports 2Health News:Mirena IUD Lawsuit News: New Complaint Filed On Behalf of Iowa Woman Claims Mirena Migrated to Her Rectum, Bernstein Liebhard LLP Reports 3Health News:Mirena IUD Lawsuit News: New Complaint Filed On Behalf of Iowa Woman Claims Mirena Migrated to Her Rectum, Bernstein Liebhard LLP Reports 4Health News:PhUSE Further Expands its Global Community Into the Asian Region 2Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 2Health News:Oaksterdam University Addresses "Why Quality Training Matters in a Growing Marijuana Industry" in First Blog Post 3Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 2Health News:Florida Hospital Zephyrhills Celebrates Grand Opening of Women’s Health Center 3Health News:Study questions accuracy of lung cancer screens in some geographic regions 2
... community-based oncology practices , , HOUSTON, June 10 ... nation,s foremost cancer treatment and research network and working with ... announces the launch of iKnowMed(TM) to ... health record (EHR) system designed by oncologists for ...
... ... $500 savings bond giveaway for expectant parents. M.A.Z.E. is dedicated to helping parents save ... ... -- Expectant parents can start investing for their child,s education with M.A.Z.E. Cord Blood Laboratories. ...
... 10 The Anthropedia Foundation, a non-profit organization with headquarters ... Switzerland, where it will host its first annual gala. The ... at Le Vieux Manoir, a five-star Relais & Chateaux Hotel ... artists, executives, doctors, scientists, and distinguished guests will enjoy a ...
... legally sell alcohol to teenagers after their sixteenth birthdays ... early age, but U.S. parents who follow this relaxed ... alcohol, should be careful -- it may increase the ... conducted by Caitlin Abar, graduate student, human development and ...
... 10 PIBH recognized 23 outstanding Pennsylvania workers and ... with disabilities, particularly in the workplace. , , ... at the Hilton Hotel in Harrisburg last night, celebrated ... day, however, PIBH honors the spirit and skills of ...
... , Havel,s partners with Canadian Hospital Specialties, to ... , , CINCINNATI, June 10 ... devices, has partnered with CHS, Canadian Hospital Specialties, ... EchoStim(R) and EchoBlock(R) Ultrasound Needles throughout Canada. , ...
Cached Medicine News:Health News:US Oncology Launches Oncology-Specific EHR to the Open Market 2Health News:US Oncology Launches Oncology-Specific EHR to the Open Market 3Health News:US Oncology Launches Oncology-Specific EHR to the Open Market 4Health News:M.A.Z.E. Cord Blood Laboratories Offers Expectant Parents The Chance To Win A $500 Savings Bond 2Health News:Anthropedia Foundation Charity Gala, Murten, Switzerland, in the Presence of HSH Prince Albert II of Monaco 2Health News:Zero tolerance alcohol policy good choice for parents 2Health News:PIBH with NFL Star Doug Flutie Recognizes 23 PA Workers with Disabilities, 21 Organizations Supporting Those with Disabilities 2Health News:PIBH with NFL Star Doug Flutie Recognizes 23 PA Workers with Disabilities, 21 Organizations Supporting Those with Disabilities 3Health News:PIBH with NFL Star Doug Flutie Recognizes 23 PA Workers with Disabilities, 21 Organizations Supporting Those with Disabilities 4Health News:PIBH with NFL Star Doug Flutie Recognizes 23 PA Workers with Disabilities, 21 Organizations Supporting Those with Disabilities 5Health News:PIBH with NFL Star Doug Flutie Recognizes 23 PA Workers with Disabilities, 21 Organizations Supporting Those with Disabilities 6Health News:Havel's Incorporated Expands Successful EchoStim(R) Ultrasound Needles into Canada 2
... groups of flexible lighting products. The first ... three different sizes 5", 10", and 15" ... the light). These lights are for use ... ,The second group of flexible lights ...
These units, though small, still offer sufficient output to ensure current is fully adjustable from 0 to 70 mA. Instruction manual, ball electrodes, battery and leads with alligator clips are include...
... two groups of flexible lighting products. The ... in three different sizes 5", 10", and ... of the light). These lights are for ... needed., ,The second group of flexible ...
Designed to be used for neuromuscular blockage monitoring. Provides for easy placement over the ulnar nerve on a patient's wrist. Dual element permits non-invasive monitoring using a single electrode...
Medicine Products: